Preferred Dosing Schedule Pledged by HCV Drug Candidate
The Editors at Hepatitis Central
March 25, 2010
Print this page
Zalbin is a Hepatitis C drug in development that could lead to the highly desired monthly or bi-monthly dosing.
Human Genome Sciences reports hepatitis drug study
The Associated Press March 24, 2010
Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment.
Continue reading this entire article:
HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.